Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like parsing medical jargon and regulatory code at once—especially when Femasys Inc. details FDA trial phases, device patents, and funding rounds in single documents. If you’ve opened the company’s 10-K only to search for pivotal FemBloc clinical data or revenue from FemaSeed, you’re not alone.
Stock Titan’s AI turns those dense reports into plain language summaries the moment they hit EDGAR. Instantly see which section of the Femasys quarterly earnings report 10-Q filing discusses cash runway, or receive real-time alerts when a director files Femasys insider trading Form 4 transactions. Our platform covers every form:
- 10-K and 10-Q filings—find R&D spend and market-launch timelines with one-click Femasys earnings report filing analysis
- 8-K updates—get Femasys 8-K material events explained, from FDA clearances to patent grants
- DEF 14A proxy—track Femasys proxy statement executive compensation and board governance tied to clinical milestones
- Form 4—monitor Femasys Form 4 insider transactions real-time to gauge executive confidence
Need answers fast? Ask natural questions like “How is FemVue revenue trending?”—our engine replies by linking the exact paragraph in the filing. Whether you’re understanding Femasys SEC documents with AI for due diligence or comparing insider buys via Femasys executive stock transactions Form 4, every disclosure is indexed, summarized, and searchable within minutes. Complex women’s-health innovations deserve clarity; we deliver it, so you can focus on investment decisions instead of page counts.
Alumni Capital LP, together with Alumni Capital GP LLC and Ashkan Mapar (the "Reporting Persons"), report beneficial ownership of 4,773,579 shares of Femasys, Inc. common stock, representing 9.99% of the class on a beneficial ownership basis. The position reflects 931,900 shares actually owned plus rights to acquire additional shares through a Purchase Agreement, a Common Warrant, and a Pre-Funded Warrant. Current warrants and the purchase agreement include ownership limitations that cap acquisitions at 4.99% unless increased to 9.99% by notice or agreement. The Reporting Persons state the holdings are not intended to change or influence control of the issuer.
Dov Elefant, Chief Financial Officer of Femasys Inc. (FEMY), purchased 38,828 Units on 08/27/2025 at $0.5151 per Unit in an underwritten public offering under Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Following the transaction, the report shows the reporting person beneficially owns 58,436 shares of common stock. The warrants have an exercise/conversion price of $0.5151, are exercisable beginning 08/27/2025 and expire 08/27/2030. The Form 4 was signed by an attorney-in-fact on 08/28/2025.
Kathy Lee-Sepsick, Chief Executive Officer and Director of Femasys Inc. (FEMY), reported purchases in an underwritten public offering. On 08/27/2025 she acquired 48,535 Units at $0.5151 per Unit, where each Unit comprises one share of common stock and one warrant to purchase one share. After the transaction she beneficially owns 360,627 shares directly and 72,223 shares indirectly through the Lee-Sepsick Family Trust. The warrants are exercisable beginning 08/27/2025 and expire 08/27/2030.
Femasys Inc. files an amendment to its S-1 registration for a public offering while describing its women’s health product portfolio and regulatory progress. The company markets FDA-cleared products including FemaSeed (intratubal insemination) and diagnostic devices and reports peer-reviewed positive clinical data. It describes FemBloc, a first-in-class non-surgical permanent birth control system whose blended polymer and delivery system received CE mark under EU MDR in March and June 2025 and subsequent UK certification in August 2025, and notes a pivotal U.S. trial (NCT05977751) is enrolling. The prospectus discloses capital-raising details, potential dilution from outstanding options, warrants and convertible notes (totaling millions of shares issuable), intended use of proceeds, a 60-day lock-up, FINRA underwriter warrants, and material risks including Nasdaq continued-listing noncompliance and financing and regulatory uncertainties.
Femasys Inc. reported in a Current Report on Form 8-K that on August 20, 2025 it issued a press release announcing that the company has secured UK regulatory approval for FemBloc Permanent Birth Control. The filing states the press release is furnished as Exhibit 99.1 and is incorporated by reference into the report. The 8-K does not include further operational, commercial or financial details within the filing text provided.
Femasys Inc. is offering common stock in an S-1 that would leave roughly 44.0 million shares outstanding immediately after the offering (or 45.7 million if underwriters fully exercise their option). The prospectus describes a registered offering with an assumed illustrative price of $0.70 per share, a 7% underwriting discount and estimated offering expenses of about $0.8 million. The company recently secured a $10 million equity line (Any Market Purchase Agreement) and reports CE mark approvals for its FemBloc system components in 2025, strategic Spanish distribution for FemBloc, and an active pivotal U.S. trial (NCT05977751). Material dilutive instruments include convertible notes convertible at $1.18 and various options and warrants. Use of proceeds is for product development, commercialization and general corporate purposes.
Femasys Inc. reported results for the quarter ended June 30, 2025. Quarterly sales rose to $409,268 (six months $750,532), driven by increased FemaSeed and FemVue sales. The company recorded a net loss of $(4,585,922) for the quarter and $(10,482,761) for the six months, with six-month net loss per share of $(0.39). Cash and cash equivalents were $3,218,067, total assets $13,780,409, total liabilities $12,272,974, and an accumulated deficit of $137,681,018. Inventory increased to $5,232,738.
The filing highlights regulatory and commercial milestones: CE mark certification under EU MDR for the FemBloc delivery system (March 2025) and for the class III blended polymer component (June 2025), strategic distribution in Spain, enrollment of the U.S. pivotal trial, and subsequent commercial and regulatory updates including an approximate $400,000 order in Spain and Australia/New Zealand approvals announced July 1, 2025. Financing activity included at-the-market sales (~$5.5M in H1 2025) and a June 2025 underwritten offering (gross $4.51M, net proceeds $3.705M). Management states substantial doubt exists about the company’s ability to continue as a going concern and discloses Nasdaq non-compliance notices with deadlines to regain compliance.
Femasys Inc. announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release as Exhibit 99.1 to this Current Report; the text states the release is being furnished, not "filed," under the Exchange Act and therefore is not subject to Section 18 liability or automatically incorporated by reference into other filings. This 8-K text does not include financial figures or operating metrics; readers must consult Exhibit 99.1 for the detailed results and corporate update. The filing identifies the company as an emerging growth company and shows its Nasdaq ticker as FEMY.
FAQ
What is the current stock price of FEMASYS (FEMY)?
What is the market cap of FEMASYS (FEMY)?
